Personalized oncology through integrative high-throughput sequencing: a pilot study.

Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol (2013) 7.97

Integrative clinical genomics of advanced prostate cancer. Cell (2015) 5.29

Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet (2013) 3.96

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol (2013) 3.71

Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol (2014) 3.70

Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat Med (2014) 3.18

Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov (2013) 3.13

Personalized genomic analyses for cancer mutation discovery and interpretation. Sci Transl Med (2015) 2.88

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med (2013) 2.66

Sailfish enables alignment-free isoform quantification from RNA-seq reads using lightweight algorithms. Nat Biotechnol (2014) 2.65

Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol (2013) 2.59

Pharmacogenomics and individualized medicine: translating science into practice. Clin Pharmacol Ther (2012) 2.48

Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur Urol (2012) 2.39

High-throughput Phenotyping of Lung Cancer Somatic Mutations. Cancer Cell (2016) 2.31

Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. Nat Genet (2013) 2.30

Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens. J Mol Diagn (2013) 2.20

IntOGen-mutations identifies cancer drivers across tumor types. Nat Methods (2013) 2.10

Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth. JAMA (2015) 2.02

Beyond PSA: the next generation of prostate cancer biomarkers. Sci Transl Med (2012) 2.00

Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases. Sci Transl Med (2014) 1.71

Detecting somatic genetic alterations in tumor specimens by exon capture and massively parallel sequencing. J Vis Exp (2013) 1.68

The current state of resident training in genomic pathology: a comprehensive analysis using the resident in-service examination. Am J Clin Pathol (2014) 1.56

Existing and emerging technologies for tumor genomic profiling. J Clin Oncol (2013) 1.52

Integrative molecular profiling of routine clinical prostate cancer specimens. Ann Oncol (2015) 1.51

Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors. Neoplasia (2015) 1.44

An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors. Sci Transl Med (2015) 1.44

Clinical analysis and interpretation of cancer genome data. J Clin Oncol (2013) 1.44

From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. J Pathol (2012) 1.42

Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers. Oncotarget (2016) 1.41

Molecular prescreening to select patient population in early clinical trials. Nat Rev Clin Oncol (2012) 1.40

Perspectives of clinical genetics professionals toward genome sequencing and incidental findings: a survey study. Clin Genet (2012) 1.38

Building a personalized medicine infrastructure at a major cancer center. J Clin Oncol (2013) 1.36

Next-generation sequencing to guide cancer therapy. Genome Med (2015) 1.31

Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer. Int J Cancer (2013) 1.27

Drug repositioning for personalized medicine. Genome Med (2012) 1.24

Prospective enterprise-level molecular genotyping of a cohort of cancer patients. J Mol Diagn (2014) 1.21

Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial. Ann Oncol (2015) 1.20

Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial. Br J Cancer (2014) 1.19

ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients. Clin Cancer Res (2015) 1.18

Translating genomic information into clinical medicine: lung cancer as a paradigm. Genome Res (2012) 1.18

Clinical actionability enhanced through deep targeted sequencing of solid tumors. Clin Chem (2015) 1.16

Advancing precision medicine for prostate cancer through genomics. J Clin Oncol (2013) 1.16

Luminal breast cancer: from biology to treatment. Nat Rev Clin Oncol (2013) 1.16

Targeted sequencing of cancer-related genes in colorectal cancer using next-generation sequencing. PLoS One (2013) 1.10

Sensitive deep-sequencing-based HIV-1 genotyping assay to simultaneously determine susceptibility to protease, reverse transcriptase, integrase, and maturation inhibitors, as well as HIV-1 coreceptor tropism. Antimicrob Agents Chemother (2014) 1.08

The genomic landscape of prostate cancer. Front Endocrinol (Lausanne) (2012) 1.07

The Distinctive Mutational Spectra of Polyomavirus-Negative Merkel Cell Carcinoma. Cancer Res (2015) 1.07

Metastatic tumor evolution and organoid modeling implicate TGFBR2 as a cancer driver in diffuse gastric cancer. Genome Biol (2014) 1.05

Integrated RNA and DNA sequencing improves mutation detection in low purity tumors. Nucleic Acids Res (2014) 1.05

Applying next-generation sequencing to pancreatic cancer treatment. Nat Rev Gastroenterol Hepatol (2012) 1.04

Organizing knowledge to enable personalization of medicine in cancer. Genome Biol (2014) 1.04

Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer. Sci Signal (2014) 1.03

Can the exome and the immunome converge on the design of efficient cancer vaccines? Oncoimmunology (2012) 1.03

Functional analysis of non-hotspot AKT1 mutants found in human breast cancers identifies novel driver mutations: implications for personalized medicine. Oncotarget (2013) 1.03

Biopsies: next-generation biospecimens for tailoring therapy. Nat Rev Clin Oncol (2013) 1.02

RNA-Seq technology and its application in fish transcriptomics. OMICS (2013) 1.02

Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implications. Clin Lung Cancer (2013) 1.01

Clinical next generation sequencing to identify actionable aberrations in a phase I program. Oncotarget (2015) 1.01

Cancer systems biology: embracing complexity to develop better anticancer therapeutic strategies. Oncogene (2014) 1.00

Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail. Br J Cancer (2014) 0.98

Personal genomes, quantitative dynamic omics and personalized medicine. Quant Biol (2013) 0.98

Translating cancer genomes and transcriptomes for precision oncology. CA Cancer J Clin (2015) 0.97

Targeted-capture massively-parallel sequencing enables robust detection of clinically informative mutations from formalin-fixed tumours. Sci Rep (2013) 0.97

The use of exome capture RNA-seq for highly degraded RNA with application to clinical cancer sequencing. Genome Res (2015) 0.97

Teaching residents genomic pathology: a novel approach for new technology. Adv Anat Pathol (2013) 0.96

Algorithm for codevelopment of new drug-predictive biomarker combinations: accounting for inter- and intrapatient tumor heterogeneity. Clin Lung Cancer (2012) 0.96

Testing personalized medicine: patient and physician expectations of next-generation genomic sequencing in late-stage cancer care. Eur J Hum Genet (2013) 0.96

Oncologists' and cancer patients' views on whole-exome sequencing and incidental findings: results from the CanSeq study. Genet Med (2016) 0.95

Successful whole-exome sequencing from a prostate cancer bone metastasis biopsy. Prostate Cancer Prostatic Dis (2013) 0.95

Clinical tumor sequencing: an incidental casualty of the American College of Medical Genetics and Genomics recommendations for reporting of incidental findings. J Clin Oncol (2014) 0.94

Integrating pathology and radiology disciplines: an emerging opportunity? BMC Med (2012) 0.93

Genomic oncology education: an urgent need, a new approach. Cancer J (2014) 0.92

The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine. Genome Med (2016) 0.92

Changing the paradigm: the potential for targeted therapy in laryngeal squamous cell carcinoma. Cancer Biol Med (2016) 0.91

Disrupting the networks of cancer. Clin Cancer Res (2012) 0.90

Germline Findings in Tumor-Only Sequencing: Points to Consider for Clinicians and Laboratories. J Natl Cancer Inst (2015) 0.90

Traditional roles in a non-traditional setting: genetic counseling in precision oncology. J Genet Couns (2014) 0.90

Clinical applications of next-generation sequencing in colorectal cancers. World J Gastroenterol (2013) 0.89

The Tip of the Iceberg: Clinical Implications of Genomic Sequencing Projects in Head and Neck Cancer. Cancers (Basel) (2015) 0.89

HLA typing from RNA-seq data using hierarchical read weighting [corrected]. PLoS One (2013) 0.88

Integrating next-generation sequencing into clinical oncology: strategies, promises and pitfalls. ESMO Open (2016) 0.88

Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma. Clin Lymphoma Myeloma Leuk (2014) 0.88

Deciphering Phosphotyrosine-Dependent Signaling Networks in Cancer by SH2 Profiling. Genes Cancer (2012) 0.88

Primary urethral clear-cell adenocarcinoma: comprehensive analysis by surgical pathology, cytopathology, and next-generation sequencing. Am J Pathol (2014) 0.86

Long insert whole genome sequencing for copy number variant and translocation detection. Nucleic Acids Res (2013) 0.86

Estrogen receptor mutations and their role in breast cancer progression. Breast Cancer Res (2014) 0.86

MSIseq: Software for Assessing Microsatellite Instability from Catalogs of Somatic Mutations. Sci Rep (2015) 0.86

Personalizing Medicine in Head and Neck Squamous Cell Carcinoma: The Rationale for Combination Therapies. Med Res Arch (2016) 0.86

Clinical application of high-throughput genomic technologies for treatment selection in breast cancer. Breast Cancer Res (2013) 0.85

Pilot studies for personalized cancer medicine: focusing on the patient for treatment selection. Oncologist (2013) 0.85

Development and clinical application of an integrative genomic approach to personalized cancer therapy. Genome Med (2016) 0.84

H19 Noncoding RNA, an Independent Prognostic Factor, Regulates Essential Rb-E2F and CDK8-β-Catenin Signaling in Colorectal Cancer. EBioMedicine (2016) 0.84

Epidemiology: Biorepositories for cancer research in developing countries. Nat Rev Clin Oncol (2013) 0.84

Next-generation sequencing in the clinical genetic screening of patients with pheochromocytoma and paraganglioma. Endocr Connect (2013) 0.84

A targeted next-generation sequencing method for identifying clinically relevant mutation profiles in lung adenocarcinoma. Sci Rep (2016) 0.84

BRAF mutation testing with a rapid, fully integrated molecular diagnostics system. Oncotarget (2015) 0.83

BreakTrans: uncovering the genomic architecture of gene fusions. Genome Biol (2013) 0.83

Chapter 14: Cancer genome analysis. PLoS Comput Biol (2012) 0.83

Identification of tumorigenic and therapeutically actionable mutations in transplantable mouse tumor cells by exome sequencing. Oncogenesis (2013) 0.83

Progress and potential: training in genomic pathology. Arch Pathol Lab Med (2014) 0.83

Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 75.40

Integrated genomic analyses of ovarian carcinoma. Nature (2011) 47.72

Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78

Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57

The protein kinase complement of the human genome. Science (2002) 35.36

Targeted capture and massively parallel sequencing of 12 human exomes. Nature (2009) 33.96

COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res (2010) 25.55

The cancer genome. Nature (2009) 23.13

International network of cancer genome projects. Nature (2010) 20.35

Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature (2010) 15.63

Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature (2009) 13.45

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol (2010) 13.25

Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature (2011) 13.18

The Human Gene Mutation Database: 2008 update. Genome Med (2009) 11.72

Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer (2009) 11.25

Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet (2010) 10.15

Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell (2011) 7.32

Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med (2010) 6.38

Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol (2010) 6.34

Tyrosine kinases as targets for cancer therapy. N Engl J Med (2005) 6.24

BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst (2003) 6.20

Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med (2010) 6.08

PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol (2009) 4.83

Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med (2010) 4.81

Use of whole-genome sequencing to diagnose a cryptic fusion oncogene. JAMA (2011) 4.11

Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell (2011) 3.53

Alterations of the PPP2R1B gene in human lung and colon cancer. Science (1998) 3.14

KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol (2010) 3.12

ChimeraScan: a tool for identifying chimeric transcription in sequencing data. Bioinformatics (2011) 2.74

Therapeutic strategies for targeting ras proteins. Genes Cancer (2011) 2.45

A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood (2010) 2.25

KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer. Mol Cancer Ther (2009) 2.22

The fusion gene Cbfb-MYH11 blocks myeloid differentiation and predisposes mice to acute myelomonocytic leukaemia. Nat Genet (1999) 2.02

An oncogenic role for ETV1 in melanoma. Cancer Res (2010) 1.94

A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice. Sci Transl Med (2011) 1.72

Early accelerated approval for highly targeted cancer drugs. N Engl J Med (2011) 1.55

Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry. J Mol Diagn (2011) 1.53

BRAF, a target in melanoma: implications for solid tumor drug development. Cancer (2010) 1.37

High throughput interrogation of somatic mutations in high grade serous cancer of the ovary. PLoS One (2011) 1.28

Unregulated smooth-muscle myosin in human intestinal neoplasia. Proc Natl Acad Sci U S A (2008) 1.20

Revving the Throttle on an oncogene: CDK8 takes the driver seat. Cancer Res (2009) 1.09

Comrad: detection of expressed rearrangements by integrated analysis of RNA-Seq and low coverage genome sequence data. Bioinformatics (2011) 1.08

New strategies in metastatic melanoma: oncogene-defined taxonomy leads to therapeutic advances. Clin Cancer Res (2011) 1.02

A protocol for genetic evaluation of patients with multiple colorectal adenomas and without evidence of APC gene mutation. Isr Med Assoc J (2010) 0.89

Do we have to change the way targeted drugs are developed? J Clin Oncol (2010) 0.88

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06

Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58

The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature (2002) 18.30

ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia (2004) 17.08

Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med (2012) 15.69

Development of human protein reference database as an initial platform for approaching systems biology in humans. Genome Res (2003) 14.79

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71

Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res (2008) 14.37

EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A (2003) 13.68

ProbeMatch: rapid alignment of oligonucleotides to genome allowing both gaps and mismatches. Bioinformatics (2009) 13.34

Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature (2009) 12.58

The mutational landscape of lethal castration-resistant prostate cancer. Nature (2012) 11.82

Transcriptome sequencing to detect gene fusions in cancer. Nature (2009) 11.63

Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature (2007) 10.94

Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia (2007) 10.74

TEAD mediates YAP-dependent gene induction and growth control. Genes Dev (2008) 9.88

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med (2012) 9.69

Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci U S A (2004) 9.42

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med (2002) 8.86

Integrative molecular concept modeling of prostate cancer progression. Nat Genet (2006) 8.49

TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res (2006) 7.61

Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science (2008) 7.59

Autoantibody signatures in prostate cancer. N Engl J Med (2005) 7.56

Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res (2002) 7.29

Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell (2009) 7.09

Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med (2012) 6.99

Statins and the risk of colorectal cancer. N Engl J Med (2005) 6.86

An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell (2010) 6.76

Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21. Nat Genet (2008) 6.75

Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol (2011) 6.54

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol (2012) 6.49

Disclosure of APOE genotype for risk of Alzheimer's disease. N Engl J Med (2009) 6.43

The emergence of lncRNAs in cancer biology. Cancer Discov (2011) 6.32

TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol (2007) 6.09

Recurrent gene fusions in prostate cancer. Nat Rev Cancer (2008) 6.08

Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell (2005) 6.04

A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell (2007) 5.99

Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia (2008) 5.92

Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res (2004) 5.88

Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol (2009) 5.45

Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst (2006) 5.42

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med (2015) 5.39

Growth of nanowire superlattice structures for nanoscale photonics and electronics. Nature (2002) 5.34

Chimeric transcript discovery by paired-end transcriptome sequencing. Proc Natl Acad Sci U S A (2009) 5.30

EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia (2008) 5.22

alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA (2002) 5.07

Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res (2002) 5.00

TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res (2006) 4.99

Recurrent reciprocal 1q21.1 deletions and duplications associated with microcephaly or macrocephaly and developmental and behavioral abnormalities. Nat Genet (2008) 4.87